Upregulation of striatal adenosine A2A receptor mRNA in 6‐hydroxydopamine‐lesioned rats intermittently treated with L‐DOPA
暂无分享,去创建一个
[1] Tzvetelina Dimitrova,et al. Adenosine A2A receptor antagonist treatment of Parkinson’s disease , 2003, Neurology.
[2] T. Suda,et al. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation , 2003, Neuroscience Letters.
[3] M. Cenci,et al. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesia , 2003, Journal of neurochemistry.
[4] E. Hirsch,et al. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6‐OHDA‐lesioned‐rats treated with l‐dopa , 2002, The European journal of neuroscience.
[5] F. Pedata,et al. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. , 2002, European journal of pharmacology.
[6] M. Morelli,et al. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats , 2002, Synapse.
[7] E. Ongini,et al. Persistent Behavioral Sensitization to Chronic l-DOPA Requires A2A Adenosine Receptors , 2002, The Journal of Neuroscience.
[8] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[9] M. Andersson,et al. Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease , 2001, The European journal of neuroscience.
[10] M. Morelli,et al. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6‐hydroxydopamine‐lesioned rats , 2001, Synapse.
[11] M. Ochi,et al. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. , 2000, European journal of pharmacology.
[12] K. Fuxe,et al. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine‐denervated striatum , 2000, The European journal of neuroscience.
[13] M. Ochi,et al. Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study , 2000, Neuroscience.
[14] P. Jenner,et al. Combined Use of the Adenosine A2A Antagonist KW-6002 with l -DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys , 2000, Experimental Neurology.
[15] P. Jenner,et al. Alterations in preproenkephalin and adenosine‐2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l‐DOPA , 2000, The European journal of neuroscience.
[16] L. Grégoire,et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys , 1999, Neurology.
[17] T. Suda,et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.
[18] T. Suda,et al. Loss of regulation by presynaptic dopamine D2 receptors of exogenous l-DOPA-derived dopamine release in the dopaminergic denervated striatum , 1999, Brain Research.
[19] J. Brotchie,et al. Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease , 1998, Experimental Neurology.
[20] P. Jenner,et al. Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.
[21] P. Svenningsson,et al. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas , 1997, Neuroscience.
[22] E. Ongini,et al. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. , 1997, European journal of pharmacology.
[23] J. Palacios,et al. Differential regional distribution of AMPA receptor subunit messenger RNAs in the human spinal cord as visualized by in situ hybridization , 1996, Neuroscience.
[24] J. Brotchie,et al. Potential of Opioid Antagonists in the Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease , 1996, Drugs & aging.
[25] G. Di Chiara,et al. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. , 1994, European journal of pharmacology.
[26] J. Vanderhaeghen,et al. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[27] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[28] Y. Agid,et al. Continuous and intermittent levodopa differentially affect basal ganglia function , 1989, Annals of neurology.
[29] J. Burgunder,et al. Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion , 2000, Journal of Neural Transmission.
[30] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .